Hematologic malignancies pose many challenges – from diagnostic subtyping, to risk stratification and even in therapy selection. At NeoGenomics, we recognize that determining which test to use, under which circumstances, and how to best incorporate NGS can be difficult.
In his presentation, Dr Lyle will touch on the broad portfolio of NGS tests available through NeoGenomics and will provide clarity on how they can be used to optimize diagnosis and care of patients with hematologic malignancies. He will also touch on best practices and offer insights on how pathologists and oncologists can best work together to further this end.
Dr. Derek Lyle
Chief Medical Officer, Clinical Services